A Phase Ib/II Study to Evaluate the Efficacy and Safety of ST-1898 in Subjects With Unresectable or Metastatic Melanoma
Latest Information Update: 15 Apr 2024
At a glance
- Drugs ST 1898 Beijing Scitech Mq Pharmaceuticals (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Scitech-Mq Pharmaceuticals
- 15 Apr 2024 New trial record